Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Significant Decline in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 361,700 shares, a decline of 28.3% from the August 31st total of 504,700 shares. Approximately 4.1% of the company’s shares are sold short. Based on an average daily volume of 5,060,000 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 5,060,000 shares, the short-interest ratio is currently 0.1 days. Approximately 4.1% of the company’s shares are sold short.

Institutional Trading of Kairos Pharma

A hedge fund recently bought a new stake in Kairos Pharma stock. Armistice Capital LLC acquired a new position in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,404,000 shares of the company’s stock, valued at approximately $1,314,000. Armistice Capital LLC owned approximately 10.25% of Kairos Pharma at the end of the most recent reporting period.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Kairos Pharma in a report on Friday, September 19th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.33.

Kairos Pharma Stock Performance

KAPA opened at $1.26 on Tuesday. The company has a market cap of $26.15 million and a PE ratio of -3.74. Kairos Pharma has a 1 year low of $0.40 and a 1 year high of $3.25. The firm has a 50 day moving average price of $1.26 and a 200 day moving average price of $0.94.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.